EPS for Alnylam Pharmaceuticals, Inc. (ALNY) Expected At $-1.48 as of May, 4

April 16, 2018 - By Jason Dias

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Corporate Logo
During Q4 2017 the big money sentiment increased to 2.03. That’s change of 1.11, from 2017Q3’s 0.92. 27 investors sold all, 47 reduced holdings as Alnylam Pharmaceuticals, Inc. ratio increased. 83 increased holdings while 67 funds amassed holdings. Funds hold 90.18 million shares thus 4.83% more from 2017Q3’s 86.02 million shares.
Fmr Ltd Liability Company has 0.22% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Adage Capital Ptnrs Grp Ltd Limited Liability Company accumulated 290,000 shs or 0.08% of the stock. Federated Invsts Incorporated Pa holds 0.23% of its capital in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 629,080 shs. M&T Savings Bank reported 4,110 shs. 2.00M are owned by State Street Corp. California Employees Retirement System invested in 196,038 shs or 0.03% of the stock. Architects Inc owns 140 shs for 0% of their capital. Sei has invested 0.02% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Us National Bank & Trust De reported 0% stake. Profund Ltd Com accumulated 29,947 shs. Metropolitan Life Communications Ny stated it has 0.01% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Point72 Asia (Hong Kong) has invested 0.11% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). 1,300 are owned by Livforsakringsbolaget Skandia Omsesidigt. Rockefeller Fincl Services accumulated 246,931 shs. Ameriprise Inc owns 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 2,600 shs.

Alnylam Pharmaceuticals, Inc. registered $38.04 million net activity with 0 insider buys and 10 insider sales since January 4, 2018. On Thursday, January 4 $4.84M worth of stock was sold by Mason Michael. On Tuesday, March 13 SHARP PHILIP A sold $2.24M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) or 15,000 shs. Shares for $234,033 were sold by KEATING LAURIE. Ausiello Dennis A sold $2.57M worth of stock or 17,117 shs. SCHIMMEL PAUL also sold $4.17M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shs. On Monday, March 26 Greenstreet Yvonne also sold $985,958 worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s earnings release is anticipated by WallStreet on May, 4, according to RTT. Analysts predict 18.40 % diference or $-1.48 from the $-1.25 EPS from 2017. 0.00 % EPS growth is what analysts predict. $-1.48 EPS was announced for last [previous quarter]. The stock decreased 3.28% or $3.3 during the last trading session, reaching $97.46.Currently Alnylam Pharmaceuticals, Inc. is uptrending after 150.73% change in last April 16, 2017. ALNY has also 479,558 shares volume. ALNY outperformed by 139.18% the S&P500.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

In total 15 analysts cover Alnylam Pharmaceuticals (NASDAQ:ALNY). “Buy” rating has 11, “Sell” are 1, while 3 are “Hold”. 73% are bullish. 30 are the (NASDAQ:ALNY)’s analyst reports since October 30, 2017 according to StockzIntelligence Inc. In Friday, December 15 report Piper Jaffray maintained the stock with “Buy” rating. On Thursday, November 2 the stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Buy” rating given by Piper Jaffray. On Friday, February 9 Jefferies maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating. Jefferies has “Buy” rating and $156.0 target. On Wednesday, November 8 the firm has “Buy” rating given by BMO Capital Markets. The stock rating was maintained by Piper Jaffray with “Buy” on Friday, November 17. On Thursday, February 8 the rating was maintained by BMO Capital Markets with “Buy”. On Friday, January 19 the stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Buy” rating given by FBR Capital. On Thursday, November 9 the company was upgraded by JP Morgan. On Friday, November 3 the rating was maintained by Needham with “Buy”. In Friday, February 2 report FBR Capital maintained the stock with “Buy” rating.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference.The firm is worth $9.76 billion. The Company’s pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases.Last it reported negative earnings. The company??s clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis ; Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: